
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc experienced a notable recovery in its financial performance during the third quarter of 2025, reporting total revenues of $4.22 million, which reflects a 105% quarter-over-quarter increase from $2.06 million in the second quarter. Additionally, the company's gross margins improved significantly to 60.3%, up from 39.8% in the previous quarter, indicating enhanced profitability amid sales growth. Furthermore, the recent non-binding merger agreement with Applied Digital Cloud indicates a strategic move that could bolster Ekso's market position and drive future growth opportunities.
Bears say
Ekso Bionics Holdings experienced a revenue shortfall relative to consensus expectations, primarily attributed to two order delays in enterprise sales amounting to $1.5 million, indicating challenges in maintaining operational momentum. In the third quarter of 2025, the company reported revenues of $4.23 million, slightly exceeding the consensus estimate of $4.16 million; however, it still suffered a significant net loss of $0.54 per share. The downgrading of the stock to a neutral rating reflects underlying concerns about the company's growth trajectory and operational effectiveness, despite modest revenue improvements.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares